Literature DB >> 12229282

[Chronic complications of polycystic ovary syndrome. Review].

Elsy Velásquez1.   

Abstract

In addition to neuroendocrine abnormalities, women with polycystic ovary syndrome have insulin resistance and beta-cell dysfunction associated with a high frequency of metabolic syndrome components, such as glucose intolerance, type 2 diabetes mellitus (DM-2), dyslipidemia and a higher risk for endothelial dysfunction, haemostatic abnormalities, hypertension and cardiovascular disease. Obesity, a common finding in this disorder, plays an important role in the development of metabolic and cardiovascular disorders. Early identification of patients and prompt initiation of insulin sensitizing therapy by pharmacological agents or changes in life style such diet and exercise might improve the metabolic and endocrine abnormalities and reduce the risk of DM-2 and cardiovascular disease in these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12229282

Source DB:  PubMed          Journal:  Invest Clin        ISSN: 0535-5133            Impact factor:   0.683


  1 in total

1.  Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1/TLR4/NF‑κB signaling pathway.

Authors:  Yijiao Yang; Ling Yang; Cao Qi; Guohua Hu; Longhui Wang; Zhuojun Sun; Xiaorong Ni
Journal:  Mol Med Rep       Date:  2020-08-28       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.